Results 61 to 70 of about 5,052,436 (221)
Intravenous Thrombolytic Therapy in Acute Ischemic Stroke
, 2012 Objective:The aim of thrombolytic treatment is to save penumbra by recanalization in acute ischemic stroke. The aim of this study was to review the efficacy and complications of intravenous thrombolytic treatment in our patients with acute ischemic ...
Canan Togay Ișıkay +1 more
core +1 more source
Cell‐Based Micro/Nanorobots: From Living Carriers to Living Therapeutic Specialists
SmartBot, EarlyView.Cell‐based micro/nanorobots integrate evolutionarily acquired biological intelligence with engineered capabilities, offering new opportunities for precision medicine in vivo. However, the complex physiological environments of different organs pose significant challenges to their clinical translation.
Junfeng Wu +12 more
wiley +1 more source
From SMART to agent systems development [PDF]
, 2005 In order for agent-oriented software engineering to prove effective it must use principled notions of agents and enabling specification and reasoning, while still considering routes to practical implementation.
Ashri, Ronald +9 more
core +1 more source
Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke
Drug Delivery, 2021 Ischemic stroke is one of the major causes of severe disability and death worldwide. It is mainly caused by a sudden reduction in cerebral blood flow due to obstruction of the supplying vessel by thrombi and subsequent initiation of a complex cascade of ...
Hongyin Ma +4 more
doaj +1 more source
Pulmonary Embolism—A Century of Progress
ANZ Journal of Surgery, EarlyView.Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley +1 more source
Thrombolysis for Prevention of Cerebral No-Reflow After Cardiopulmonary Resuscitation
Общая реаниматология, 2009 Thrombolytic treatment during cardiopulmonary resuscitation is thought to reverse the cerebral no-reflow phenomenon which is widely considered to limit neurological recovery after prolonged cardio-circulatory arrest.
K. -A. Hossmann +2 more
doaj +1 more source
Acta Biochimica Polonica, 2008 To develop a more potent antithrombin agent with thrombolytic and antiplatelet properties, a new staphylokinase (SAK) variant was constructed. The kringle 2 domain (K2) of tissue type-plasminogen activator (t-PA) containing a fibrin-specific binding site
M. Kowalski +9 more
semanticscholar +1 more source
Voice Fundamental Frequency Variation and Statin Therapy
Clinical Otolaryngology, EarlyView.ABSTRACT Objectives Statins are considered a first‐line treatment for dyslipidaemia, being the most frequently prescribed medicine worldwide. However, statin therapy has been associated with several adverse effects, including statin‐associated myopathy, which may manifest with symptoms such as myalgia, muscle stiffness, and cramps.
Luca Francesco Parata +5 more
wiley +1 more source
CLINICAL CASE OF RUSSIAN THROMBOLYTIC AGENT FORTELYZIN® USE IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE [PDF]
, 2015 One of the three clinical examples of hospital thrombolysis using Russian thrombolytic agent recombinant protein comprising an amino acid sequence of staphylokinase is described.
A. V. Krasnopeev +2 more
core +1 more source
Hemodialysis International, EarlyView.ABSTRACT Background Hemodialysis access thrombosis is the primary cause of access failure. Thrombus removal is an effective strategy to restore access function. Although both open surgical and endovascular procedures enable thrombus clearance, endovascular thrombus reduction therapy is widely adopted in clinical practice for this condition due to its ...
Lin Li +5 more
wiley +1 more source